This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical siteSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

Menu

Close

AboutAboutTherapy Area OverviewRisk Factors of Ulcerative ColitisDiagnosingDiagnosingSigns and SymptomsComorbidities & PathophysiologyTreatmentTreatment guidelinesPfizer Treatment OptionsDisease NavigatorDisease NavigatorDisease NavigatorTreatmentTreatment guidelinesPfizer Treatment Options

Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information. Adverse event reporting can be found at the bottom of the page.


Therapy Area Overview: Ulcerative ColitisDifferent Extents & The Severity of UCDifferent Extents & The Severity of UC

In UC, inflammation begins in the rectum and spreads continuously to involve part or all of the colon. UC is categorised based on the extent of disease in the colon1.

Different types of Ulcerative ColitisDifferent types of Ulcerative Colitis

Click on the drop downs below to learn about each type of UC.

Proctitis
  • Approximately 55% of patients fall into this category2.
  • Inflammation is limited to the rectum.
 Proctosigmoiditis
  • Inflammation involves the rectum and sigmoid colon3.
 Left-sided colitis
  • Approximately 25% of patients fall into this category2.
  • Inflammation extends from the rectum through the descending colon but does not extend past the splenic flexure3.
 Pancolitis
  • Also known as "extensive colitis"1.
  • Approximately 20% of patients fall into this category2.
  • Inflammation extends past the splenic flexure3.
Distinguishing between Ulcerative Colitis and Crohn's Disease


UC and CD are the two main inflammatory bowel diseases. While both diseases involve ongoing inflammation in the GI tract, there are important differences between the two1.
 

Ulcerative Colitis
  • UC is more prevalent than CD1.
  • UC is charcterised by uniform inflammation in the GI tract4.
  • UC is restricted to the colon and the rectum5.
  • Surgery (removal of the entire colon) may cure UC4.
  • The hallmark symptom is bloody diarrhea4.
Crohn's Disease
  • CD is characterised by patchy areas of gut inflammation6.
  • CD can affect any region of the GI tract, from the mouth to the anus6.
  • Surgery cannot cure CD4.
  • The most characteristic symptoms are abdominal pain and diarrhea (with or without blood)6.
 Learning Academy
Inflammation Disease Navigator

Click below to view the Immuno-navigator tool. An interactive tool to help you manage discussions with your patients . 

 Visit the Navigator Tool
Patient Support Materials (pdf)

References

Ordás I. Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012; 380:1606-1619.Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5):329-342.Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014; 89(11):1553-1563.Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011; 365:1713-1725.Crohn’s and Colitis Foundation of America. The facts about inflammatory bowel diseases. 2014. [Document on the Internet]. 2014 Jan 1 [cited 2016 Dec 14]. Available from: http://www.ccfa.org/assets/pdfs/updatedibdfactbook.pdf.Kalla R, Ventham NT, Satsangi J, Arnott IDR. Crohn's disease. BMJ. 2014; 349:
PP-IFA-GBR-0635. July 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​